BJC Reports, Published online: 15 September 2026; doi:10.1038/s44276-026-00249-3 Immune remodeling and myeloid signature in the bone marrow niche of MYCN -driven neuroblastoma
Bethel Tesfai Embaie, Adele M. Alchahin, Lilly Velentza, Thale Kristin Olsen, Ioana Maria Gavriliuc, Shenglin Mei et al. Immune remodeling and myeloid signature in the bone marrow niche of MYCN-driven neuroblastoma. // BJC Reports. – 2026. – DOI: 10.1038/s44276-026-00249-3. – URL: https://www.nature.com/articles/s44276-026-00249-3
Bethel Tesfai Embaie, Adele M. Alchahin, Lilly Velentza, Thale Kristin Olsen, Ioana Maria Gavriliuc, Shenglin Mei, & Ninib Baryawno (2026). Immune remodeling and myeloid signature in the bone marrow niche of MYCN-driven neuroblastoma. BJC Reports. https://doi.org/10.1038/s44276-026-00249-3
Bethel Tesfai Embaie, et al. “Immune remodeling and myeloid signature in the bone marrow niche of MYCN-driven neuroblastoma.” BJC Reports, 2026. doi:10.1038/s44276-026-00249-3.
@article{Embaie2026,
title = {Immune remodeling and myeloid signature in the bone marrow niche of MYCN-driven neuroblastoma},
author = {Embaie, Bethel Tesfai and Alchahin, Adele M. and Velentza, Lilly and Olsen, Thale Kristin and Gavriliuc, Ioana Maria and Mei, Shenglin and Baryawno, Ninib},
journal = {BJC Reports},
year = {2026},
doi = {10.1038/s44276-026-00249-3},
url = {https://www.nature.com/articles/s44276-026-00249-3}
}
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05030-x Comment on: ‘Association of accelerometer-monitored physical activity with incident cataract: epidemiological and genetic evidence’
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05032-9 NAION during incretin-based therapy: an optic nerve head still adapted to hypertension
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05016-9 Comparing refractive errors in CACNA1F and CABP4 -associated disease in a UK cohort
Eye, Published online: 19 November 2026; doi:10.1038/s41433-026-05018-7 Comment on: ‘Determinants of regression kinetics in observed stage 3 retinopathy of prematurity without plus disease’